245 related articles for article (PubMed ID: 32788653)
1. EGFR/FOXO3a/BIM signaling pathway determines chemosensitivity of BMP4-differentiated glioma stem cells to temozolomide.
Ciechomska IA; Gielniewski B; Wojtas B; Kaminska B; Mieczkowski J
Exp Mol Med; 2020 Aug; 52(8):1326-1340. PubMed ID: 32788653
[TBL] [Abstract][Full Text] [Related]
2. ANGPTL4 Induces TMZ Resistance of Glioblastoma by Promoting Cancer Stemness Enrichment via the EGFR/AKT/4E-BP1 Cascade.
Tsai YT; Wu AC; Yang WB; Kao TJ; Chuang JY; Chang WC; Hsu TI
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717924
[TBL] [Abstract][Full Text] [Related]
3. Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2.
Xu L; Duan H; Zou Y; Wang J; Liu H; Wang W; Zhu X; Chen J; Zhu C; Yin Z; Zhao X; Wang Q
Phytomedicine; 2023 Jun; 114():154764. PubMed ID: 36963368
[TBL] [Abstract][Full Text] [Related]
4. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
[TBL] [Abstract][Full Text] [Related]
5. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells.
Guan H; Song L; Cai J; Huang Y; Wu J; Yuan J; Li J; Li M
PLoS One; 2011; 6(5):e19946. PubMed ID: 21625639
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner.
Nabissi M; Morelli MB; Amantini C; Liberati S; Santoni M; Ricci-Vitiani L; Pallini R; Santoni G
Int J Cancer; 2015 Oct; 137(8):1855-69. PubMed ID: 25903924
[TBL] [Abstract][Full Text] [Related]
8. Specific Preferences in Lineage Choice and Phenotypic Plasticity of Glioma Stem Cells Under BMP4 and Noggin Influence.
Videla Richardson GA; Garcia CP; Roisman A; Slavutsky I; Fernandez Espinosa DD; Romorini L; Miriuka SG; Arakaki N; Martinetto H; Scassa ME; Sevlever GE
Brain Pathol; 2016 Jan; 26(1):43-61. PubMed ID: 25808628
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway.
Peng L; Ming Y; Zhang L; Zhou J; Xiang W; Zeng S; He H; Chen L
FASEB J; 2020 Apr; 34(4):5128-5143. PubMed ID: 32067282
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Tomar VS; Patil V; Somasundaram K
Cell Biol Toxicol; 2020 Jun; 36(3):273-278. PubMed ID: 31758290
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
Li X; Tao Z; Wang H; Deng Z; Zhou Y; Du Z
Exp Cell Res; 2020 Nov; 396(1):112261. PubMed ID: 32896567
[TBL] [Abstract][Full Text] [Related]
13. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
15. Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells.
Sareddy GR; Pratap UP; Venkata PP; Zhou M; Alejo S; Viswanadhapalli S; Tekmal RR; Brenner AJ; Vadlamudi RK
Stem Cells; 2021 May; 39(5):536-550. PubMed ID: 33470499
[TBL] [Abstract][Full Text] [Related]
16. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma.
Huang W; Zhong Z; Luo C; Xiao Y; Li L; Zhang X; Yang L; Xiao K; Ning Y; Chen L; Liu Q; Hu X; Zhang J; Ding X; Xiang S
Theranostics; 2019; 9(19):5497-5516. PubMed ID: 31534499
[TBL] [Abstract][Full Text] [Related]
17. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Gong X; Schwartz PH; Linskey ME; Bota DA
Neurology; 2011 Mar; 76(13):1126-34. PubMed ID: 21346220
[TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic protein 4 inhibits cell proliferation and induces apoptosis in glioma stem cells.
Zhou Z; Sun L; Wang Y; Wu Z; Geng J; Miu W; Pu Y; You Y; Yang Z; Liu N
Cancer Biother Radiopharm; 2011 Feb; 26(1):77-83. PubMed ID: 21355779
[TBL] [Abstract][Full Text] [Related]
19. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
20. Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers.
Verploegh ISC; Conidi A; Brouwer RWW; Balcioglu HE; Karras P; Makhzami S; Korporaal A; Marine JC; Lamfers M; Van IJcken WFJ; Leenstra S; Huylebroeck D
Neuro Oncol; 2022 Dec; 24(12):2133-2145. PubMed ID: 35639831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
